BioCentury
ARTICLE | Clinical News

Innate sees no development path for lirilumab combo therapies

December 1, 2017 10:21 PM UTC

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to patients or an obvious development path." The partners said they are in discussions to decide on a path forward for the candidate.

The double-blind, placebo-controlled, international trial evaluated the combination in about 650 patients with platinum refractory, recurrent or metastatic head and neck cancer. The trial is also evaluating a triplet combination of lirilumab, Opdivo and Yervoy ipilimumab to treat advanced refractory solid tumors...